Connection

James Ballenger to Adult

Back to Details
This is a "connection" page, showing publications James Ballenger has written about Adult.
James Ballenger
Connection Strength
0.557
Adult
  1. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.021
  2. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707.
    View in: PubMed
    Score: 0.017
  3. Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2004; 65 Suppl 1:55-62.
    View in: PubMed
    Score: 0.016
  4. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
    View in: PubMed
    Score: 0.015
  5. A brief scale for assessing patients' satisfaction with care in outpatient psychiatric services. Psychiatr Serv. 2001 Jun; 52(6):816-9.
    View in: PubMed
    Score: 0.013
  6. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry. 2000 Nov 15; 48(10):962-70.
    View in: PubMed
    Score: 0.013
  7. Recognizing the patient with social anxiety disorder. Int Clin Psychopharmacol. 2000 Jul; 15 Suppl 1:S1-5.
    View in: PubMed
    Score: 0.012
  8. Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
    View in: PubMed
    Score: 0.011
  9. Sleep Deprivation in social phobia and generalized anxiety disorder. Biol Psychiatry. 1998 Jun 01; 43(11):840-2.
    View in: PubMed
    Score: 0.011
  10. Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol. 1998 Apr; 13 Suppl 4:S13-7.
    View in: PubMed
    Score: 0.011
  11. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42.
    View in: PubMed
    Score: 0.010
  12. Sleep deprivation in panic disorder and obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov; 42(9):982-3.
    View in: PubMed
    Score: 0.010
  13. Discussion and overview: what can we learn if we view panic disorder across the life span and across different presentations and contexts? Bull Menninger Clin. 1997; 61(2 Suppl A):A95-102.
    View in: PubMed
    Score: 0.010
  14. Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S.
    View in: PubMed
    Score: 0.009
  15. The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety. 1996; 2(4):157-66.
    View in: PubMed
    Score: 0.009
  16. Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995 Nov; 152(11):1665-7.
    View in: PubMed
    Score: 0.009
  17. Sertraline in social phobia. J Clin Psychopharmacol. 1995 Oct; 15(5):372-3.
    View in: PubMed
    Score: 0.009
  18. CSF isatin is elevated in bulimia nervosa. Biol Psychiatry. 1995 Apr 01; 37(7):481-3.
    View in: PubMed
    Score: 0.009
  19. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
    View in: PubMed
    Score: 0.008
  20. Comorbidity of axis I psychiatric disorders in bulimia nervosa. J Clin Psychiatry. 1995 Feb; 56(2):77-80.
    View in: PubMed
    Score: 0.008
  21. Plasma pyridoxal phosphate in anxiety disorders. Biol Psychiatry. 1994 Nov 01; 36(9):606-8.
    View in: PubMed
    Score: 0.008
  22. Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry. 1994 Sep 15; 36(6):425-7.
    View in: PubMed
    Score: 0.008
  23. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry. 1994 Jun; 151(6):930-2.
    View in: PubMed
    Score: 0.008
  24. Panic disorder and gastrointestinal symptoms: findings from the NIMH Epidemiologic Catchment Area project. Am J Psychiatry. 1994 Jan; 151(1):64-70.
    View in: PubMed
    Score: 0.008
  25. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug; 150(8):1216-8.
    View in: PubMed
    Score: 0.008
  26. CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am J Psychiatry. 1993 Jul; 150(7):1099-101.
    View in: PubMed
    Score: 0.008
  27. Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia. Br J Psychiatry. 1993 Jun; 162:788-9; discussion 790-4.
    View in: PubMed
    Score: 0.008
  28. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
    View in: PubMed
    Score: 0.008
  29. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993 May-Jun; 34(3):229-34.
    View in: PubMed
    Score: 0.007
  30. Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
    View in: PubMed
    Score: 0.007
  31. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
    View in: PubMed
    Score: 0.007
  32. Tricyclic antidepressant triggers mania in patient with organic affective disorder. J Clin Psychiatry. 1992 Oct; 53(10):377-8.
    View in: PubMed
    Score: 0.007
  33. CSF beta-endorphin and dynorphin in bulimia nervosa. Am J Psychiatry. 1992 Aug; 149(8):1086-90.
    View in: PubMed
    Score: 0.007
  34. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol. 1992; 47:431-47.
    View in: PubMed
    Score: 0.007
  35. Cardiovascular status of panic disorder patients with and without prominent cardiac symptoms. Psychosomatics. 1992; 33(1):81-4.
    View in: PubMed
    Score: 0.007
  36. Cocaine-induced psychosis. J Clin Psychiatry. 1991 Dec; 52(12):509-12.
    View in: PubMed
    Score: 0.007
  37. Treatment of social phobia with bupropion. J Clin Psychopharmacol. 1991 Aug; 11(4):276-7.
    View in: PubMed
    Score: 0.007
  38. Fluoxetine treatment of voyeurism. Am J Psychiatry. 1991 Jul; 148(7):950.
    View in: PubMed
    Score: 0.007
  39. Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6.
    View in: PubMed
    Score: 0.006
  40. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9.
    View in: PubMed
    Score: 0.006
  41. Pergolide mesylate treatment of cocaine withdrawal. J Clin Psychiatry. 1991 Jan; 52(1):39-40.
    View in: PubMed
    Score: 0.006
  42. Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan; 36(1):45-9.
    View in: PubMed
    Score: 0.006
  43. Panic and phobic disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1990 Nov; 51(11):456-8.
    View in: PubMed
    Score: 0.006
  44. Rapid response of patients simultaneously treated with lithium and nortriptyline. J Clin Psychiatry. 1990 Mar; 51(3):124-5.
    View in: PubMed
    Score: 0.006
  45. Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol. 1989 Dec; 9(6):428-31.
    View in: PubMed
    Score: 0.006
  46. Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment. J Clin Psychiatry. 1989 Sep; 50(9):356-7.
    View in: PubMed
    Score: 0.006
  47. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
    View in: PubMed
    Score: 0.006
  48. Electroencephalography during sleep of patients with panic disorder. J Neuropsychiatry Clin Neurosci. 1989; 1(4):372-6.
    View in: PubMed
    Score: 0.006
  49. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
    View in: PubMed
    Score: 0.005
  50. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
    View in: PubMed
    Score: 0.005
  51. Precursor amino acid concentrations in normal weight bulimics and normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12(6):893-8.
    View in: PubMed
    Score: 0.005
  52. Alprazolam in the treatment of social phobia. J Clin Psychiatry. 1988 Jan; 49(1):17-9.
    View in: PubMed
    Score: 0.005
  53. Can panic disorder present as irritable bowel syndrome? J Clin Psychiatry. 1986 Sep; 47(9):470-3.
    View in: PubMed
    Score: 0.005
  54. Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport. 2004 Dec 22; 15(18):2701-5.
    View in: PubMed
    Score: 0.004
  55. Psychopharmacology of the anxiety disorders. Psychiatr Clin North Am. 1984 Dec; 7(4):757-71.
    View in: PubMed
    Score: 0.004
  56. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984; 20(3):572-84.
    View in: PubMed
    Score: 0.004
  57. Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003; 37(4):66-72.
    View in: PubMed
    Score: 0.004
  58. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980 Jul; 137(7):782-90.
    View in: PubMed
    Score: 0.003
  59. Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000; 12(2):111-3.
    View in: PubMed
    Score: 0.003
  60. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999 Jul; 60(7):427-35.
    View in: PubMed
    Score: 0.003
  61. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry. 1999 May; 60(5):299-301.
    View in: PubMed
    Score: 0.003
  62. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979 Feb; 36(2):224-7.
    View in: PubMed
    Score: 0.003
  63. Feasibility of using fMRI to study mothers responding to infant cries. Depress Anxiety. 1999; 10(3):99-104.
    View in: PubMed
    Score: 0.003
  64. Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry. 1997 Jun; 154(6):766-72.
    View in: PubMed
    Score: 0.002
  65. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
    View in: PubMed
    Score: 0.002
  66. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996 Dec; 57(12):576-8.
    View in: PubMed
    Score: 0.002
  67. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry. 1996 Apr 15; 39(8):703-7.
    View in: PubMed
    Score: 0.002
  68. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
    View in: PubMed
    Score: 0.002
  69. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 01; 37(7):462-6.
    View in: PubMed
    Score: 0.002
  70. Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res. 1995 Mar-Apr; 29(2):121-31.
    View in: PubMed
    Score: 0.002
  71. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord. 1994 Jan; 30(1):5-13.
    View in: PubMed
    Score: 0.002
  72. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in patients with anxiety disorders. J Neuropsychiatry Clin Neurosci. 1993; 5(3):335-7.
    View in: PubMed
    Score: 0.002
  73. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry. 1992 Nov; 149(11):1556-62.
    View in: PubMed
    Score: 0.002
  74. CSF diazepam-binding inhibitor concentrations in panic disorder. Biol Psychiatry. 1992 Oct 15; 32(8):712-6.
    View in: PubMed
    Score: 0.002
  75. Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol. 1992 Oct; 12(5):352-4.
    View in: PubMed
    Score: 0.002
  76. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992 May; 149(5):691-3.
    View in: PubMed
    Score: 0.002
  77. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103.
    View in: PubMed
    Score: 0.002
  78. CSF opioids in panic disorder. Biol Psychiatry. 1991 Sep 01; 30(5):512-4.
    View in: PubMed
    Score: 0.002
  79. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32.
    View in: PubMed
    Score: 0.002
  80. Cocaine abuse among schizophrenic patients. Am J Psychiatry. 1990 Sep; 147(9):1164-7.
    View in: PubMed
    Score: 0.002
  81. CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990 Feb; 147(2):225-9.
    View in: PubMed
    Score: 0.001
  82. Sequence of improvement in agoraphobia with panic attacks. J Psychiatr Res. 1990; 24(1):1-8.
    View in: PubMed
    Score: 0.001
  83. CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 1989 Jul; 26(3):257-64.
    View in: PubMed
    Score: 0.001
  84. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989 May; 146(5):617-21.
    View in: PubMed
    Score: 0.001
  85. Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. J Affect Disord. 1989 Jan-Feb; 16(1):49-58.
    View in: PubMed
    Score: 0.001
  86. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26.
    View in: PubMed
    Score: 0.001
  87. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May; 45(5):423-8.
    View in: PubMed
    Score: 0.001
  88. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987 May; 144(5):664-5.
    View in: PubMed
    Score: 0.001
  89. The effects of lithium on neuroendocrine function in affectively ill patients. Acta Psychiatr Scand. 1986 May; 73(5):524-8.
    View in: PubMed
    Score: 0.001
  90. Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch Gen Psychiatry. 1986 Apr; 43(4):392-6.
    View in: PubMed
    Score: 0.001
  91. Neuroendocrine effects of carbamazepine in patients with affective illness. Epilepsia. 1986 Mar-Apr; 27(2):156-60.
    View in: PubMed
    Score: 0.001
  92. Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol. 1986; 9(5):448-55.
    View in: PubMed
    Score: 0.001
  93. The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol. 1985 Apr; 5(2):100-2.
    View in: PubMed
    Score: 0.001
  94. Tetrahydrobiopterin levels in cerebrospinal fluid of affectively ill patients. Lancet. 1983 Jul 02; 2(8340):55-6.
    View in: PubMed
    Score: 0.001
  95. CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry. 1983 Jul; 40(7):743-7.
    View in: PubMed
    Score: 0.001
  96. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry. 1983 Jun; 40(6):673-6.
    View in: PubMed
    Score: 0.001
  97. CSF somatostatin in affective illness. Arch Gen Psychiatry. 1983 Apr; 40(4):409-12.
    View in: PubMed
    Score: 0.001
  98. The effect of lithium on the osmoregulation of arginine vasopressin secretion. J Clin Endocrinol Metab. 1983 Feb; 56(2):295-9.
    View in: PubMed
    Score: 0.001
  99. Neurohypophyseal function in affective illness. Psychopharmacol Bull. 1983; 19(3):426-31.
    View in: PubMed
    Score: 0.001
  100. Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45.
    View in: PubMed
    Score: 0.001
  101. Cerebrospinal fluid hydroxylase cofactor in schizophrenia. Psychiatry Res. 1982 Apr; 6(2):145-51.
    View in: PubMed
    Score: 0.001
  102. Central nervous system gamma-aminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch Neurol. 1982 Apr; 39(4):247-9.
    View in: PubMed
    Score: 0.001
  103. Endorphins in the cerebrospinal fluid of psychiatric patients. Ann N Y Acad Sci. 1982; 398:399-412.
    View in: PubMed
    Score: 0.001
  104. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec; 38(12):1315-7.
    View in: PubMed
    Score: 0.001
  105. Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry. 1981 Nov; 138(11):1457-62.
    View in: PubMed
    Score: 0.001
  106. Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Res. 1981 Aug; 5(1):87-93.
    View in: PubMed
    Score: 0.001
  107. The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981 Aug; 138(8):1045-50.
    View in: PubMed
    Score: 0.001
  108. Slow and rapid onset of manic episodes: implications for underlying biology. Psychiatry Res. 1981 Apr; 4(2):229-37.
    View in: PubMed
    Score: 0.001
  109. Effects of vasopressin on human memory functions. Science. 1981 Feb 06; 211(4482):601-3.
    View in: PubMed
    Score: 0.001
  110. Cerebrospinal fluid amine metabolites and cyclic nucleotides in human aggression [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):63-5.
    View in: PubMed
    Score: 0.001
  111. Plasma and CSF MHPG in normals [proceedings]. Psychopharmacol Bull. 1981 Jan; 17(1):86-7.
    View in: PubMed
    Score: 0.001
  112. Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid. Neurology. 1980 Sep; 30(9):1008-11.
    View in: PubMed
    Score: 0.001
  113. Immunoreactive calcitonin in cerebrospinal fluid of man. Brain Res. 1980 Aug 04; 194(2):598-602.
    View in: PubMed
    Score: 0.001
  114. Rapid mood cycling and concomitant cortisol changes produced by cyproheptadine. Am J Psychiatry. 1980 Mar; 137(3):378-9.
    View in: PubMed
    Score: 0.001
  115. Dopamine beta-hydroxylase in CSF. Relationship to personality measures. Arch Gen Psychiatry. 1980 Mar; 37(3):308-10.
    View in: PubMed
    Score: 0.001
  116. Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science. 1980 Jan 18; 207(4428):331-3.
    View in: PubMed
    Score: 0.001
  117. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan; 37(1):51-9.
    View in: PubMed
    Score: 0.001
  118. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979 Oct; 1(2):131-9.
    View in: PubMed
    Score: 0.001
  119. Low cerebrospinal fluid gamma-aminobutyric acid content in seizure patients. Neurology. 1979 Sep; 29(9 Pt 1):1203-8.
    View in: PubMed
    Score: 0.001
  120. Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry. 1979 Apr; 14(2):337-44.
    View in: PubMed
    Score: 0.001
  121. Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry. 1978 Dec; 13(6):685-94.
    View in: PubMed
    Score: 0.001
  122. Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram. Biol Psychiatry. 1977 Oct; 12(5):635-42.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.